Tele: 561.316.3330
Breaking Medical Device News

Thursday, September 23, 2021
HomeReForm BiologicsReForm Biologics Announces Issuance of U.S. Patent for New Excipient to Improve Antibody-Based Therapeutics

ReForm Biologics Announces Issuance of U.S. Patent for New Excipient to Improve Antibody-Based Therapeutics


“Many antibody-based therapeutics need to be delivered intravenously due to their high dose requirements and viscosity in solution. Subcutaneous injection of a highly concentrated antibody solution is a preferred route for patients that require frequent and longer term treatment,” said John M. Sorvillo PhD, Chief Executive Officer.

ReForm Biologics, a pharmaceutical technology company developing an innovative platform to improve biologic formulations, announced today the issuance of U.S. patent 9,605,051 (the ‘051 patent) for one of its new excipient formulations.

An important application of the technology in this patent, entitled “Viscosity-Reducing Excipient Compounds for Protein Formulations,” covers the use of a new excipient that significantly reduces the viscosity of highly concentrated therapeutic antibody solutions. ReForm believes that viscosity reduction will allow for more effective formulation and preferable delivery of such antibody solutions to patients.

“Many antibody-based therapeutics need to be delivered intravenously due to their high dose requirements and viscosity in solution. Subcutaneous injection of a highly concentrated antibody solution is a preferred route for patients that require frequent and longer term treatment,” said John M. Sorvillo PhD, Chief Executive Officer. “The new excipient technology in the ‘051 patent enables high concentration formulations and will further enhance ReForm’s innovative platform for viscosity reduction of biotherapeutics. This new patent is a cornerstone of our proprietary technology platform to improve biologic formulations.”

ReForm Biologics also announced it will present a poster titled “A Fresh Perspective on Biologic Formulations” on May 3rd and May 4th at the 13th Annual PEGS Boston Summit at the Seaport World Trade Center in Boston, MA.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy